Jamie Murray s Top Picks: April 26, 2021
JPMorgan is preparing to offer a bitcoin fund to wealthy clients
Wall Street splits on dollarâs fate amid economic growth debate
Chinaâs biggest IPO this year looks to be in renewable power
What rotation? Some winning COVID stocks thrive amid reopening
Wall Streetâs trillion-dollar ESG club comes with huge tax perks
Darren Sissons Top Picks: April 23, 2021
A baseball card SPAC shows why distressed investing is so hard
Archegos thwarts Nomura s push to join Wall Street elite
Citi retail units seen fetching US$6B as sales kick off
Housing shock could upend Canadian asset values: Wolf
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Vaccitech Completes $168 Million Series B Financing to Advance Three Clinical Programs Through .
Vaccitech LimitedMarch 17, 2021 GMT
OXFORD, United Kingdom, March 17, 2021 (GLOBE NEWSWIRE) Vaccitech Ltd (“Vaccitech”), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announces that it has raised $168 million in a Series B financing. This includes $43 million in convertible loan notes previously issued by Vaccitech that converted into Series B shares.
The Series B financing round was led by M&G Investment Management (part of M&G plc), with further participation from new investors including Tencent, Gilead Sciences, Monaco Constitutional Reserve Fund, and Future Planet Capital among others. The Series B financing round was also support
Future Planet Capital: Future Planet Invests in Vaccitech s Series B Financing
Future Planet Capital has invested in a $168m Series B financing announced today by Vaccitech Ltd. Future Planet joins other leading investors including M&G Investment Management, Tencent, Gilead Sciences, Monaco Constitutional Reserve Fund and fellow existing investor, Oxford Sciences Innovation. As part of the Series B financing, $43 million in convertible loan notes previously issued by Vaccitech will convert into Series B shares, resulting in total gross proceeds to Vaccitech of $168 million before expenses.
Douglas Hansen-Luke, Executive Chairman of Future Planet Capital, explained: Our decision to support Vaccitech last year, before the results of the COVID-19 Vaccine AstraZeneca trials were known, has been vindicated by the vaccine s approval for emergency use by national and international regulators. The success of the COVID-19 Vaccine AstraZeneca has increased our confidence in Vaccitech s im
Posted on 7556
Future Planet Capital has invested in a $168m Series B financing announced today by Vaccitech Ltd. Future Planet joins other leading investors including M&G Investment Management, Tencent, Gilead Sciences, Monaco Constitutional Reserve Fund and fellow existing investor, Oxford Sciences Innovation. As part of the Series B financing, $43 million in convertible loan notes previously issued by Vaccitech will convert into Series B shares, resulting in total gross proceeds to Vaccitech of $168 million before expenses.
Douglas Hansen-Luke, Executive Chairman of Future Planet Capital, explained:
“Our decision to support Vaccitech last year, before the results of the COVID-19 Vaccine AstraZeneca trials were known, has been vindicated by the vaccine’s approval for emergency use by national and international regulators. The success of the COVID-19 Vaccine AstraZeneca has increased our confidence in Vaccitech’
Get the latest industry news first when you subscribe to our daily newsletter.
We will never sell or share your information without your consent. See our privacy policy.